Table 2.
Clinical characteristics
| Culprit plaques (n=17) | Non-culprit plaques (n=6) | Renal arteries (n=15) | |
|---|---|---|---|
| Age (years) | 72 (64–76) | 71 (55–72) | 55 (41–63) |
| Sex, male | 14 (82) | 5 (83) | 5 (33) |
| Stenosis degree (%) | |||
| 70–99 | 14 (82) | 6 (100) | – |
| 50–69 | 2 (12) | – | – |
| < 50 | 1 (6) | – | – |
| Presenting symptoms | |||
| Stroke | 9 (53) | – | – |
| TIA | 7 (41) | – | – |
| Amaurosis fugax | 1 (6) | – | – |
| Cardiovascular history | 8 (47) | 6 (100) | 0 |
| Coronary artery disease | 3 (18) | 3 (50) | – |
| Cerebrovascular diseasea | 4 (24) | 6 (100) | – |
| Peripheral artery disease | 4 (24) | 2 (33) | – |
| Diabetes mellitus | 1 (6) | 3 (50) | 0 |
| Current smoker | 6 (34) | 2 (33) | 6 (40) |
| BMI (kg/m2) | 25 (23–30) | 31 (29–31) | 26 (24–28) |
| SBP (mm Hg) | 139 (132–150) | 144 (127–173) | 134 (127–148) |
| DBP (mm Hg) | 76 (60–83) | 73 (68–78) | 76 (70–83) |
| Total cholesterol (mmol/L) | 4.4 (3.5–6.1) | 4.2 (3.4–10) | 5.5 (4.8–6.2) |
| LDL cholesterol (mmol/L) | 3 (2.2–3.8) | 2.5 (2.0–8.2) | 3.1 (2.7–4.1) |
| Medicationb | |||
| Antihypertensives | 9 (53) | 3 (50) | 3 (20) |
| Statins | 7 (41) | 6 (100) | 1 (6) |
| Antiplatelet therapy | 5 (29) | 6 (100) | 0 |
| Anticoagulation | 3 (18) | 0 | 0 |
Data are expressed as number (%) or median (interquartile range)
TIA, transient ischemic attack; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein
aIn culprit plaques: other than current event
bIn culprit plaques: medication use prior to the recent cerebrovascular event